Biogen confirms Icahn ally is on board - Atlanta Business Chronicle:

exceeding-commissioner.blogspot.com
Shareholders were to elect four directors at the Biogen was pushing for the reelectionj of all ofthe company’sw existing directors, while Icahn was angling to seat four new According to Biogen Idec, shareholders appear to have reelectedr current directors Robert Pangia and William D. and elected Icahn ally Alexander Denner. Biogen Idec officials say the vote for the fourtj seat is too closeto call. Bioge n said the company will rely on the tabulation of votesz by its independent inspector of IVS Associates, before announcing the remaining director to serve on the Bruce R.
Ross, Biogen Idec’a chairman, said, “We welcome our new director to the boars and look forward to working together to buildf on our strong track record ofdeliveringg value. While we await the outcome of the vote for the remaining director, we would like to express our gratitude for the supporr of our stockholders.” Icahn, in a filing with the Securities and Exchangee Commission, accused the company of preventing the votes cast from being counted. “If the board is successful, Richard Mulligan, a prominent scientist and physician, may be kept from legitimately being elected tothe board.
” Mulligan is the Mallinckrodt Professor of Geneticz at Harvard Medical School and director of the Harvars Gene Therapy Initiative, according to Harvard University’s Web Biogen said shareholders rejected several of Icahn’ other proposals, including moving the company’ incorporation from Delaware to North Dakota, a move Icahm said would give more power to Biogen officials said it appearss that stockholders also rejected a proposal by Icahmn to limit the size of the boarfd to 13 directors. Biogen officials now have the power to enlarge the board as theysee fit. Icahn is best knowm for unsuccessfully pushing BiogenIdec (Nasdaq: to sell itself in 2008.
Last year, shareholderxs elected the company’s nominees over the slate of investors put up by Biogen Idec’s (NASDAQ: BIIB) stoc k was trading at $53.17 in afternoon trading Thursday, down from the previousx day’s close of $53.43 a share.